Skip to main content

Remote Job Finders (RJF)

While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.
Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
Scroll to top